Qelbree approval date?

See the DrugPatentWatch profile for Qelbree

When was Qelbree (viloxazine) approved?

Qelbree (viloxazine extended-release) received FDA approval on April 26, 2021, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults. [1]

Has Qelbree’s approval expanded since the original date?

FDA approvals can later expand to additional age groups or new indications, but the original approval date was April 26, 2021. If you want, tell me the age group or indication you care about, and I can help pinpoint the relevant FDA action. [1]

What’s the best place to check official timelines?

For drug timeline details and related patent/exclusivity context, DrugPatentWatch.com is a useful reference. [2]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211785
[2] https://www.drugpatentwatch.com/